Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: A case report
Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a rare disorder caused by somatic mosaicism for the gain of function RAS mutations . Affected patients have segmental epidermal nevi, dysplastic cortical bony lesions, and fibroblast growth factor-23 (FGF23)–mediated hypophosphatemic rickets. He...
Main Authors: | Manal Khadora, M. Zulf Mughal |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-12-01
|
Series: | Bone Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352187221003958 |
Similar Items
-
Burosumab for the treatment of cutaneous-skeletal hypophosphatemia syndrome
by: Lillian Abebe, et al.
Published: (2024-03-01) -
A Case Report: First Long-Term Treatment With Burosumab in a Patient With Cutaneous-Skeletal Hypophosphatemia Syndrome
by: Lea Maria Merz, et al.
Published: (2022-05-01) -
Complications and Treatments in Adult X-Linked Hypophosphatemia
by: Yasuo Imanishi, et al.
Published: (2022-09-01) -
Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia
by: Silvia Martín Ramos, et al.
Published: (2020-02-01) -
Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children
by: Aaron Schindeler, et al.
Published: (2020-05-01)